{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T22:11:29Z","timestamp":1757628689904,"version":"3.44.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Daiichi Sankyo, Seoul, Republic of Korea"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Hypertens"],"DOI":"10.1038\/s41371-025-01043-3","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T06:40:47Z","timestamp":1752475247000},"page":"675-678","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness of single-pill combination olmesartan\/amlodipine\/hydrochlorothiazide therapy in patients with apparent resistant hypertension"],"prefix":"10.1038","volume":"39","author":[{"given":"Jaewon","family":"Oh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wonho","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gee-Hee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6703-1472","authenticated-orcid":false,"given":"Hack-Lyoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Don","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung Wan","family":"Min","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongkeun","family":"Hyun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun Hwa","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soo","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Hwan","family":"Bae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6706-6504","authenticated-orcid":false,"given":"Jinho","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the RESOLVE-INT Investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,14]]},"reference":[{"key":"1043_CR1","doi-asserted-by":"publisher","first-page":"e079108","DOI":"10.1136\/bmj-2023-079108","volume":"385","author":"EL Schiffrin","year":"2024","unstructured":"Schiffrin EL, Fisher NDL. Diagnosis and management of resistant hypertension. BMJ. 2024;385:e079108.","journal-title":"BMJ"},{"key":"1043_CR2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s40885-023-00255-4","volume":"29","author":"S Park","year":"2023","unstructured":"Park S, Shin J, Ihm SH, Kim KI, Kim HL, Kim HC, et al. Resistant hypertension: consensus document from the Korean society of hypertension. Clin Hypertens. 2023;29:30.","journal-title":"Clin Hypertens"},{"key":"1043_CR3","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s11906-022-01173-w","volume":"24","author":"LCC Brant","year":"2022","unstructured":"Brant LCC, Passaglia LG, Pinto-Filho MM, de Castilho FM, Ribeiro ALP, Nascimento BR. The burden of resistant hypertension across the world. Curr Hypertens Rep. 2022;24:55\u201366.","journal-title":"Curr Hypertens Rep"},{"key":"1043_CR4","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/s41440-019-0284-9","volume":"42","author":"S Umemura","year":"2019","unstructured":"Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese society of hypertension guidelines for the management of hypertension (JSH 2019). Hypertens Res. 2019;42:1235\u2013481.","journal-title":"Hypertens Res"},{"key":"1043_CR5","doi-asserted-by":"publisher","first-page":"4817","DOI":"10.1007\/s12325-023-02632-9","volume":"40","author":"J Oh","year":"2023","unstructured":"Oh J, Kim W, Kim GH, Kim HL, Park SD, Min KW, et al. Real-world effectiveness and safety of a single-pill combination of olmesartan\/amlodipine\/hydrochlorothiazide in Korean patients with hypertension and cardiovascular risk factors. Adv Ther. 2023;40:4817\u201335.","journal-title":"Adv Ther"},{"key":"1043_CR6","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40885-019-0124-x","volume":"25","author":"HY Lee","year":"2019","unstructured":"Lee HY, Shin J, Kim GH, Park S, Ihm SH, Kim HC, et al. 2018 Korean society of hypertension guidelines for the management of hypertension: part II-diagnosis and treatment of hypertension. Clin Hypertens. 2019;25:20.","journal-title":"Clin Hypertens"},{"key":"1043_CR7","doi-asserted-by":"publisher","first-page":"3500","DOI":"10.1007\/s12325-020-01404-z","volume":"37","author":"SJ Park","year":"2020","unstructured":"Park SJ, Rhee SJ. Real-world effectiveness and safety of a single-pill combination of olmesartan\/amlodipine\/hydrochlorothiazide in Korean patients with essential hypertension (RESOLVE): a large, observational, retrospective, cohort study. Adv Ther. 2020;37:3500\u201314.","journal-title":"Adv Ther"},{"key":"1043_CR8","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40885-016-0043-z","volume":"22","author":"KN Lee","year":"2015","unstructured":"Lee KN, Na JO, Choi CU, Lim HE, Kim JW, Kim EJ, et al. Prevalence and characteristics of resistant hypertension at primary clinics in Korea: a nationwide cross-sectional study. Clin Hypertens. 2015;22:4.","journal-title":"Clin Hypertens"},{"key":"1043_CR9","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1038\/s41440-021-00845-5.","volume":"45","author":"M Yoon","year":"2022","unstructured":"Yoon M, You SC, Oh J, Lee CJ, Lee SH, Kang SM, et al. Prevalence and prognosis of refractory hypertension diagnosed using ambulatory blood pressure measurements. Hypertens Res. 2022;45:1353\u201362. https:\/\/doi.org\/10.1038\/s41440-021-00845-5.","journal-title":"Hypertens Res"},{"key":"1043_CR10","doi-asserted-by":"publisher","first-page":"888","DOI":"10.3904\/kjim.2019.361","volume":"36","author":"S Kim","year":"2021","unstructured":"Kim S, Park JJ, Shin MS, Kwak CH, Lee BR, Park SJ, et al. Apparent treatment-resistant hypertension among ambulatory hypertensive patients: a cross-sectional study from 13 general hospitals. Korean J Intern Med. 2021;36:888\u201397.","journal-title":"Korean J Intern Med"},{"key":"1043_CR11","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1093\/eurheartj\/ehab499.","volume":"42","author":"AM Jackson","year":"2021","unstructured":"Jackson AM, Jhund PS, Anand IS, Dungen HD, Lam CSP, Lefkowitz MP, et al. Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. Eur Heart J. 2021;42:3741\u201352. https:\/\/doi.org\/10.1093\/eurheartj\/ehab499.","journal-title":"Eur Heart J"},{"key":"1043_CR12","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40885-016-0045-x","volume":"22","author":"SI Choi","year":"2015","unstructured":"Choi SI, Kim SK, Park S, Kim JH, Ihm SH, Kim GI, et al. Prevalence of resistant hypertension and associated factors for blood pressure control status with optimal medical therapy using Korean ambulatory blood pressure monitoring registry data. Clin Hypertens. 2015;22:8.","journal-title":"Clin Hypertens"}],"container-title":["Journal of Human Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41371-025-01043-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41371-025-01043-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41371-025-01043-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T10:05:02Z","timestamp":1757498702000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41371-025-01043-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,14]]},"references-count":12,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["1043"],"URL":"https:\/\/doi.org\/10.1038\/s41371-025-01043-3","relation":{},"ISSN":["1476-5527"],"issn-type":[{"type":"electronic","value":"1476-5527"}],"subject":[],"published":{"date-parts":[[2025,7,14]]},"assertion":[{"value":"4 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Jaewon Oh, Wonho Kim, Gee-Hee Kim, Hack-Lyoung, Sang-Don Park, Kyung Wan Min, Dongkeun Hyun, Jun Hwa Hong, and Soo Lim declare that they have no competing interests. Ji-Hwan Bae is a full-time employee of Daiichi Sankyo Korea Co., Ltd. Jinho Shin received honoraria from Daiichi Sankyo, Organon, Bristol Myers Squibb, Menarini, Sanofi, Hanmi, Boryung, Chong Kun Dang, and Daewoong, and grants from Sanofi and Hanmi.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was conducted according to ethical principles established by the Declaration of Helsinki. The Review Boards of participating institutions approved the protocol. All patients provided informed written consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}